Replies to post #189487 on Vivos Inc (RDGL)

[rogers711]

Profitable??? They don't sell a single item for profit... they also are no where near 3+ mill even in rev to cover bare min operating expenses 

[hotmeat]

Not beyond the realm of possible but it will be wholly dependent on several facets quickly coming to fruition, as evidenced by the following statements by Vivos.

Licensing agreement(s) being signed for the Gel and the continued rapid expansion of Isopet could potentially propel us to profitability.

As we know, Akina is already offering Vivos's tech for sale on its platform.

Maybe our resident Vivos ""expert"" should try reading a bit more instead of making ignorant statements about our potential road to profitability in 2025.




The Company intends to explore the viability of leveraging its technology to develop other businesses unrelated to the Company’s principal business of focusing on cancer treatment. The Company has engaged Akina, Inc. (“Akina”), a research company, to explore the viability of such initiatives. Akina would likely be the principal distributor, as the Company will remain focused on cancer treatment. Alternatively, each business opportunity could potentially be spun off as a separate business activity to an interested party. To date, Akina’s focus has been on:

? Controlled Laboratory Chilling - Akina has advised that it is easier to purchase laboratory devices to control heating, as there are limited or no options for controlled cooling, which is a common laboratory requirement often involving ice baths. The Company is now testing a prototype universal laboratory cooling device.

? Hydrogel – The Company spent years refining the development of its hydrogel, in which gelation initiates just above room temperature and is completed as it warms to body temperature. The Company is currently investing in quantifying and controlling the hydrogel resorption characteristics. There has been sufficient spontaneous interest in this component to warrant a serious business case assessment. The Company has trademarked the name Precision GelTM and, in addition to its current hydrogel patent, has filed a new provisional patent in January 2025 to cover retention, transport, and release of a broad range of agents. These agents include radioactive and non-radioactive materials, solid particles, including nano-particles, large molecules, small molecules, including liquids, cells, and viruses. A memorandum of understanding (“MOU”) has been drafted to interface with potential clients including licensing and exclusive material contracting. Initial meetings are scheduled in the first half of 2025 with potential clients to assess the business viability.